Solid oral dosage forms
View Patent ↗The present invention provides pharmaceutical compositions suitable for oral delivery of active agent, such as peptides and small molecules, and methods for treating subjects in need thereof. The pharmaceutical compositions of the present invention enhance the bioavailability of therapeutic active agents.
1. A modified release solid oral composition comprising:
(a) a core comprising: (i) an effective amount of active pharmaceutical ingredient, wherein the active pharmaceutical ingredient is a peptide, a peptidomimetic, a small molecule, or a combination thereof, (ii) coated acid particles, wherein the acid particles are coated with a water soluble coat and wherein the acid of the coated acid particles is a pH lowering agent, (iii) an absorption enhancer, (iv) a filler comprising a hydrogel-forming polymer, wherein a 2% solution of the hydrogel-forming polymer has a viscosity between 3,000 to 120,000 cP at 20° C., and (v) less than 0.01% by weight of disintegrant, wherein the active pharmaceutical ingredient, the coated acid particles, the absorption enhancer, the filler and the less than 0.01% disintegrant are intermixed; and
(b) about 5 mg/cm 2 to about 25 mg/cm 2 of an enteric coating surrounding the core, wherein the composition provides a pharmacokinetic profile of the active pharmaceutical ingredient with a T lag greater than 1.0 h and less than 16 h post-administration and a T max greater than (T lag +0.5 h) and less than 20 h post-administration;
wherein, if the composition was added to ten milliliters of 0.1 M aqueous sodium bicarbonate solution, the pH of the solution would be lowered to no higher than 5.5.
2. The composition of claim 1 further comprising a water soluble barrier beneath the enteric coating.
3. The composition of claim 1 wherein the absorption enhancer has a critical micelle concentration of from about 1.0 mM to about 40 mM.
4. The composition of claim 1 wherein the filler comprises microcrystalline cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, chitosan or a combination thereof.
5. The composition of claim 1 wherein the absorption enhancer comprises a cationic surface active agent, an anionic surface active agent or a combination thereof.
6. The composition of claim 1 wherein the coated acid particles comprises citric acid, tartaric acid or a combination thereof.
7. The composition of claim 1 comprising from about 50 mg to about 500 mg of coated acid particles.
8. The composition of claim 1 , wherein the peptide is one of leuprolide, insulin, vasopressin, calcitonin, calcitonin gene-related peptide, parathyroid hormone, desmopressin, gonadotrophin releasing hormone (GnRH), luteinizing hormone-releasing factor, erythropoietin, tissue plasminogen activators, human growth hormone, adrenocorticotropin, interleukins, enkephalin, glucagon-like peptide-1, desmopressin, or 2,6-dimethyltyrosine-D-arginine-phenylalanine-lysine amide.
9. The composition of claim 1 , wherein the small molecule is classified as BCS Class II, BCS Class III or BCS Class IV.
10. The composition of claim 9 wherein the small molecule is one of tigecycline, zanamivir, kanamycin, tobramycin, or fenofibrate.
11. The composition of claim 2 wherein the water soluble barrier is in amount from about 6% to about 15% by weight.
12. The composition of claim 1 wherein the pharmacokinetic release profile targets release of the pharmaceutical active ingredient to the jejunum, the ileum or the jejunum and the ileum.
13. The composition of claim 1 , wherein the coated acid particles comprise citric acid, tartaric acid or a combination thereof.
14. The composition of claim 13 , wherein the water soluble coat separates the acid from the active pharmaceutical ingredient.
15. A modified release solid oral composition comprising:
(a) a core comprising: (i) an effective amount of active pharmaceutical ingredient, wherein the active pharmaceutical ingredient is a peptide, a peptidomimetic, a small molecule, or a combination thereof, (ii) coated acid particles, wherein the acid particles are coated with a water soluble coat and wherein the acid of the coated acid particles is a pH lowering agent, (iii) an absorption enhancer, (iv) a filler comprising a hydrogel-forming polymer, wherein a 2% solution of the hydrogel-forming polymer has a viscosity between 3,000 to 120,000 cP at 20° C., wherein the core is free of disintegrant, wherein the active pharmaceutical ingredient, the coated acid particles, the absorption enhancer, and the filler are intermixed; and
(b) about 5 mg/cm 2 to about 25 mg/cm 2 of an enteric coating surrounding the core, wherein the composition provides a pharmacokinetic profile of the active pharmaceutical ingredient with a T lag greater than 1.0 h and less than 16 h post-administration and a T max greater than (T lag +0.5 h) and less than 20 h post-administration;
wherein, if the composition was added to ten milliliters of 0.1 M aqueous sodium bicarbonate solution, the pH of the solution would be lowered to no higher than 5.5.
16. A method of treating a patient comprising (a) providing a solid oral dosage form comprising (i) a core comprising: an effective amount of active pharmaceutical ingredient, wherein the active pharmaceutical ingredient is a peptide, a peptidomimetic, a small molecule, or a combination thereof, coated acid particles, wherein the acid particles are coated with a water soluble coat and wherein the acid of the coated acid particles is a pH lowering agent, an absorption enhancer, a filler comprising a hydrogel-forming polymer, wherein a 2% solution of the hydrogel-forming polymer has a viscosity between 3,000 to 120,000 cP at 20° C., and less than 0.01% by weight of disintegrant, wherein the active pharmaceutical ingredient, the coated acid particles, the absorption enhancer, the filler and the less than 0.01% disintegrant are intermixed; and (ii) about 5 mg/cm 2 to about 25 mg/cm 2 of an enteric coating surrounding the core; (b) administering orally to a patient, the solid oral dosage form, wherein the composition provides a pharmacokinetic profile of the active pharmaceutical ingredient with a T lag greater than 1.0 h and less than 16 h post-administration and a T max greater than (T lag +0.5 h) and less than 20 h post-administration;
wherein, if the composition was added to ten milliliters of 0.1 M aqueous sodium bicarbonate solution, the pH of the solution would be lowered to no higher than 5.5.
17. The method of claim 16 wherein the pharmacokinetic profile targets release of the pharmaceutical active ingredient to the jejunum, the ileum or the jejunum and the ileum.